| General Information | |
|---|---|
| ZINC ID | ZINC000299832160 |
| Molecular Weight (Da) | 503 |
| SMILES | Cc1cc2c(s1)Cc1c(C(=O)N[C@@H]3C[C@@H](C)CC[C@@H]3C(C)C)nn(-c3ccc(Cl)cc3Cl)c1-2 |
| Molecular Formula | C26Cl2N3O1S1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 137.006 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 33 |
| LogP | 7.367 |
| Activity (Ki) in nM | 5.129 |
| Polar Surface Area (PSA) | 75.16 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.713 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 16 |
| Fraction csp3 | 0.46 |
| Ilogp | 4.52 |
| Xlogp3 | 8.01 |
| Wlogp | 7.31 |
| Mlogp | 5.47 |
| Silicos-it log p | 7.43 |
| Consensus log p | 6.55 |
| Esol log s | -8.03 |
| Esol solubility (mg/ml) | 0.00000468 |
| Esol solubility (mol/l) | 9.32E-09 |
| Esol class | Poorly sol |
| Ali log s | -9.44 |
| Ali solubility (mg/ml) | 0.00000018 |
| Ali solubility (mol/l) | 3.62E-10 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.61 |
| Silicos-it solubility (mg/ml) | 0.00000124 |
| Silicos-it solubility (mol/l) | 2.46E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.68 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 5.04 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.807 |
| Logd | 6.505 |
| Logp | 7.625 |
| F (20%) | 0.001 |
| F (30%) | 0.022 |
| Mdck | 1.37E-05 |
| Ppb | 0.9993 |
| Vdss | 2.663 |
| Fu | 0.021 |
| Cyp1a2-inh | 0.102 |
| Cyp1a2-sub | 0.67 |
| Cyp2c19-inh | 0.868 |
| Cyp2c19-sub | 0.782 |
| Cl | 5.601 |
| T12 | 0.015 |
| H-ht | 0.819 |
| Dili | 0.951 |
| Roa | 0.822 |
| Fdamdd | 0.785 |
| Skinsen | 0.035 |
| Ec | 0.003 |
| Ei | 0.007 |
| Respiratory | 0.458 |
| Bcf | 2.361 |
| Igc50 | 5.151 |
| Lc50 | 6.65 |
| Lc50dm | 5.717 |
| Nr-ar | 0.011 |
| Nr-ar-lbd | 0.042 |
| Nr-ahr | 0.84 |
| Nr-aromatase | 0.919 |
| Nr-er | 0.77 |
| Nr-er-lbd | 0.544 |
| Nr-ppar-gamma | 0.884 |
| Sr-are | 0.796 |
| Sr-atad5 | 0.01 |
| Sr-hse | 0.726 |
| Sr-mmp | 0.943 |
| Sr-p53 | 0.958 |
| Vol | 485.09 |
| Dense | 1.033 |
| Flex | 0.192 |
| Nstereo | 3 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 2 |
| Qed | 0.318 |
| Synth | 3.861 |
| Fsp3 | 0.462 |
| Mce-18 | 101.053 |
| Natural product-likeness | -1.142 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Rejected |